KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) FCF Margin (2019 - 2025)

Historic FCF Margin for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to 42.55%.

  • Royalty Pharma's FCF Margin rose 443900.0% to 42.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.2%, marking a year-over-year increase of 495800.0%. This contributed to the annual value of 11.63% for FY2024, which is 254200.0% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's FCF Margin is 42.55%, which was up 443900.0% from 62.71% recorded in Q2 2025.
  • Royalty Pharma's 5-year FCF Margin high stood at 104.71% for Q1 2025, and its period low was 147.88% during Q3 2021.
  • Its 5-year average for FCF Margin is 19.44%, with a median of 55.28% in 2021.
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 1584000bps in 2023, then crashed by -1148100bps in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's FCF Margin stood at 55.28% in 2021, then rose by 2bps to 56.51% in 2022, then crashed by -168bps to 38.52% in 2023, then surged by 208bps to 41.46% in 2024, then tumbled by -203bps to 42.55% in 2025.
  • Its FCF Margin was 42.55% in Q3 2025, compared to 62.71% in Q2 2025 and 104.71% in Q1 2025.